EGFR and lung adenocarcinoma: All patients received EGFR-TKI as the first-line therapy and demonstrated dramatic response or primary resistance to EGFR-TKI, including eight and six women, respectively, nine and six patients with lung adenocarcinomas, respectively, and non-smokers (n = 7 in both cases) with median PFS of 21 months and 1.8 months, respectively.